NCT02408770View on ClinicalTrials.gov

Breast Cancer - Anti-Progestin Prevention Study 1

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 22, 2016

Primary Completion Date

March 18, 2019

Study Completion Date

January 25, 2023

Conditions
Breast Cancer
Interventions
DRUG

ulipristal acetate

selective progesterone receptor modulator

Trial Locations (1)

M204BX

University Hospitals of South Manchester, Manchester

All Listed Sponsors
collaborator

University of Manchester

OTHER

lead

Manchester University NHS Foundation Trust

OTHER_GOV

NCT02408770 - Breast Cancer - Anti-Progestin Prevention Study 1 | Biotech Hunter | Biotech Hunter